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1.1 Immune checkpoints’ role in immune response mechanism 
 
 The progress of immuno therapy strategies for oncology is based on the 
insight that the development of cancer, which involves progressive mutations, is 
monitored by the immune system. A process termed immunoediting or immune 
surveillance eliminates most incipient tumors. A subset of cancer mutations generate 
protein coding sequence changes called neoantigens, which can be processed into 
peptide antigens; these molecules are presented by the major histocompatibility 
complex (MHC) and recognized as foreign by T cells. Neoantigens are the primary 
targets for immunoediting (1). The ultimate amplitude and quality of the T cell-
mediated responses, initiated through antigen recognition by the T cell receptor (TCR), 
are regulated by a balance between co-stimulatory and inhibitory molecules, called 
immune checkpoints. In particular, inhibitory immune checkpoints are physiologically 
involved in maintaining self-tolerance, T-cell homeostasis and protect tissue from 
damage during infections (Fig. 1). 
 The immune response to cancer evolves over many years and ultimately 
fails. One reason is that the expression of immune-checkpoint proteins can be 
dysregulated by tumors as an important immune resistance mechanism (2). The 
antitumor immune response has many characteristics of a chronic immune response to 
viral infections, with T cell inhibition mediated by the overexpression of multiple 
inhibitory immune checkpoint receptors on lymphocytes, such as programmed cell 
death protein 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), T cell 
immunoglobulin and mucin domain 3 (Tim-3; also known as HAVCR2), lymphocyte 
activation gene 3 (Lag-3), T cell immunoglobulin and ITIM domain (TIGIT), among 
others (1). In addition, tumors that evade immunoediting often express molecules that 
are able to inhibit the antitumor immune response, including programmed cell death 1 
ligand 1 (PD-L1), whose upregulation creates a feedback loop which generates 
























1.2 Biological role of PD-1 
 
 PD-1 is a surface receptor upregulated on immune cells immediately 
after activation (3). It is expressed by subsets of tolerant T cells, regulatory T (Treg) 
cells, T follicular helper (TFH) cells, T follicular regulatory (TFR) cells and memory T 
cells but it could also be expressed on B cells, Natural Killer cells (NKs), some myeloid 
cells, and even on tumor cells (4). PD-1 is a crucial regulator of adequate T cell 
responses. It is upregulated on naive T cells following initial antigen-mediated TCR 
engagement and has a key role in effector T cell activation, differentiation and in the 
development of immunological memory (5,6). Furthermore, PD-1 is essential for the 
generation and selection of high-quality, high-affinity antibodies by regulating the 
properties and abundance of antigen-stimulated CD4+ T cells (7). 
The intracellular domain of PD-1 contains an immunoreceptor tyrosine-based inhibitory 
motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM); these 
domains act by recruiting phosphatases, including SHP2 (also known as PTPN11) and 
SHP1, when PD-1 engaged with its ligands (8). 
Figure 1. Multiple co-stimulatory and inhibitory interactions regulate responses of T cells.  
[Mahoney KM Nat Rev Drug Discov 2015] 
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SHP2 and SHP1 dephosphorylate kinases and antagonize positive signals that occur 
through the TCR and CD28 stimulation, affecting downstream signaling pathways. In 
particular, they can prevent lymphocyte-specific protein tyrosine kinase (LCK)-
mediated phosphorylation of the protein kinase ZAP70, affecting the TCR signaling 
pathway. In addition, PD-1 can inhibit CD28-induced activation of 
Phosphatidylinositide 3 Kinase (PI3K), leading to reduced AKT (also known as PKB, 
Protein Kinase B) and Mammalian Target of Rapamycin (mTOR) activation, 
implicating PD-1 in survival, proliferation and altered metabolism. PD-1 can also 
modulate the Ras pathway influencing the cell cycle. Together, these alterations result 
in decreased activation of different transcription factors as NFAT, NF-kB and AP-1 (5). 
Of note Hui and his colleagues demonstrated that PD-1 recruits preferentially SHP2 and 
that the co-receptor CD28 is the main substrate for PD-1-SHP2 dephosphorylation. 
Interestingly, although costimulation via CD28 is usually correlated with naïve T cell 
priming, there is increasing evidence that it may have a role at later stages of immune 
response in chronic viral infection and in cancer (9). 
Alternative ways of PD-1-mediated inhibition are to increase transcription factor BATF, 
involved in downregulation of effector programs, and to affect T cell motility, stability 
and/or duration of T cell – antigen-presenting cell (APC) interactions (6,10) (Fig. 2). 
PD-1 could be expressed on activated CD8+ T cells and CD4+ T cells, including Tregs: 
interestingly, PD-1 upregulated on Treg cells and its interaction with PD-1 ligand on 
effector T cells may represent one cause for the potent T cell suppression and proposes 
the role of PD-1 on Treg cells (11). 
 
PD-1 could interact with two different ligands: PD-L1 (also known as B7-H1 and 
CD274) and PD-L2 (also known as B7-DC and CD273), both B7 family members. PD-
L1 is widely expressed by many different cell types and is found on both 
haematopoietic cells (including T cells, B cells, dendritic cells (DCs) and macrophages) 
and on non-haematopoietic cells (including vascular and stromal endothelial cells, 
pancreatic islet cells, placental syncytiotrophoblasts and keratinocytes) but notably also 
on tumor cells. Pro-inflammatory signals, such as interferon (IFN)-γ, produced by 
activated T cells, are involved in the upregulation of PD-L1 on tumor cells and on cells 
of the tumor microenvironment (12). By contrast, PD-L2 expression is much more 




B7 family members are negative regulators of immune response, physiologically 
important in peripheral tolerance. For example, it has been demonstrated that PD-L1 on 
pancreatic islets could prevent diabetes inducing an inhibitory signal to self-reactive 
CD4+ T cells (13). 
 
 
Figure 2. Mechanism of PD-1 signaling in T cells. 
Signalling motifs are indicated in yellow boxes; circles indicate key proteins involved in 
signalling pathways and main transcription factors. Abbreviations: ITIM, immunoreceptor 
tyrosine-based inhibitory motif; ITSM, immunoreceptor tyrosine-based switch motif; TCR, T 
cell receptor; pMHCI, peptide-Major Histocompatibility Complex class I; SHP2, Src homology 
region 2 domain-containing phosphatase; PI3K, Phosphatidylinositide 3 Kinase ; ZAP70, Zeta-
chain-associated protein kinase 70; LCK, lymphocyte-specific protein tyrosine kinase; BATF, 
basic leucine zipper transcription factor, ATF-like; AP-1, activator protein 1; NFAT,  nuclear 




Inhibitory signals are used in many ways to maintain balance in the immune system. 
Perturbing the PD-1 pathway can profoundly impact host physiology. Mice genetically 
deficient in Pdcd1 (which encodes PD-1) develop accelerated autoimmunity, as lupus-
like disease, arthritis and cardiomyopathies (14,15). Conversely, the persistent antigen 
presentation and inflammatory signals occurring during chronic infections and cancer 
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induce continue activation of immune cells and upregulation of PD-1 on their surface. 
This persistent stimulation causes an altered functional state of T cells, called 
exhaustion.  
 
Several studies demonstrate that exhausted T cells are not inert and that they can be 
reinvigorated (10,16). Thus, blocking the PD-1 pathway can improve T cell functions 
and reduce viral load and tumor burden (6). 
Another important mechanism involved in PD-1 expression is the epigenetic regulation 
(occurring during differentiation): Ghoneim et al. demonstrated that de novo DNA 
methylation of Pdcd 1 locus is involved in exhaustion and inhibits anti-PD-1-mediated 
reinvigoration (17).  
Increasing evidence of a connection between PD-1 expression and metabolism are 
currently emerging. TCR and CD28 signaling usually induce enhance glucose and 
glutamine metabolism. PD-1 engagement can modulate metabolic reprogramming 
during early phases of T cell activation by inhibiting glycolysis and promoting lipolysis 
and fatty acid oxidation (18). It has also been demonstrated that in tumor 
microenvironment occurs a metabolic competition through glucose sequestration, thus 
inducing hyporesponsive T cells and tumor progression (19). Recent studies 
demonstrated that mitochondrial activation by bezafibrate, an agonists of peroxisome 
proliferator–activated receptor gamma (PPARγ) coactivator 1-a (PGC-1a), had 
synergistic effects with a PD-1–blockade in a mouse tumor model, since T cell 
activation and differentiation are associated with mitochondrial energy metabolism (20). 
  
 
1.3 Biological role of others immune checkpoints 
 
CTLA-4. Together with PD-1 is the inhibitory immune checkpoint molecule most 
actively studied in the field of clinical cancer therapy. It is expressed by T cells and 
CD4+ Tregs. In particular, CTLA-4 is a target gene of Foxp3, the transcription factor 
characteristic of Treg cell lineage (21). CTLA-4 counteracts CD28 pathway and 
produces an inhibitory signal, through competition with the costimulatory molecule 
CD28 for the B7 ligands B7-1 (CD80) and B7-2 (CD86), for which CTLA-4 has higher 
avidity and affinity. It has a role in early stages of activation in secondary lymphoid 
organs and its expression level depends on the amplitude of the initial TCR-mediated 
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signaling. In addition, CTLA-4 also attenuates T-cell activation in peripheral tissues 
given that B7 ligands are constitutively expressed by antigen-presenting cells (APC) to 
varying degrees, but can also be expressed by activated T cells (22). In naive T cells 
CTLA-4 molecules are stored in intracellular vesicles, but after TCR engagement they 
are immediately transported to cell surface (2). Although the exact pathway of CTLA-4 
is still under debate, different studies suggest that activation of the protein phosphatases, 
SHP2 and PP2A, is important in counteracting kinase signals that are induced by TCR 
and CD28 (23). However, CTLA-4 also acts through the sequestration of CD80 and 
CD86 from CD28 engagement. The central role of CTLA-4 for keeping T cell 
activation under control is dramatically demonstrated by the fatal autoimmunity 
observed in CTLA-4-deficient mice, due to hyperactivation of lymphocytes (24,25).  
CTLA-4 had been the first immune checkpoint receptor to be clinically targeted. 
Ipilimumab (an anti-CTLA-4 monoclonal antibody) is the first-generation immune 
checkpoint inhibitor, approved by US Food and Drug Administration (FDA) in 2011. 
Different studies demonstrated its efficacy in melanoma patients, with 10% of objective 
clinical response (26) and improved OS (27). Despite the remarkable progress achieved 
with monotherapies, there is a urgent need to improve efficacy across tumor types, also 
because the high immune-related toxicities that occur with this drug (26). To date 
several clinical trials propose combination therapies with ipilimumab, in lower doses 
than monotherapy, and other immune checkpoint blockers, in order to optimize 
antitumor treatment (28).  
 
 
Tim-3. Tim-3 is an inhibitory receptor first identified as a transmembrane protein 
expressed on CD4+ T helper type 1, but then described also on CD8+ T cells, on CD4+ 
Treg cells and on innate immune cells (DC, NK cells, monocytes)(29,30). The known 
ligands of Tim-3 are galectin-9 (Gal-9), high mobility group protein B1 (HMGB1), 
carcinoembryonic antigen cell adhesion molecule 1 (Ceacam-1), and phosphatidylserine 
(PtdSer) (29). Current data show that the Tim-3 cytoplasmic tail contains five conserved 
tyrosine residues that can be phosphorylated by either Src kinases. Tim-3 interacts with 
multiple components of the TCR complex and influences the balance of Bat-3 (HLA-B 
associated transcript 3) versus Fyn, both of which bind to the same region on the 
cytoplasmic tail of Tim-3. Ligand binding triggers the dissociation of Bat-3 from the 
cytoplasmic domain of Tim-3, thus allowing Fyn to bind at the same site and promote 
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the inhibitory function of Tim-3 (29). This receptor plays a positive role in protection 
from autoimmunity but it also contributes dampening immune response against tumor 
and chronic infections. Tim-3 is highly co-expressed with PD-1 on a subset of CD8+ T 
cells exhibiting dysfunctional or exhausted phenotype, but its alone presence is not 
sufficient to induce T cell exhaustion process (30). However, expression of Tim-3 could 
be sufficient to drive resistance to anti PD-1/PD-L1 therapy and for this reason 
combinational therapies are necessary in the future.  
Furthermore, although Tim-3 is primarily considered as a marker of T-cell activation 
and exhaustion, Tim-3 also has a role to attenuate NK cell cytotoxicity (31). 
 
Lag-3. It’s another checkpoint inhibitory receptor, upregulated on CD4+ T cells, in 
particular on Tregs, on CD8+ T cells and on a subset of NK cells (32). Lag-3 binds to 
MHC class II molecules with higher affinity than CD4 co-receptor. Currently, 
additional ligands for Lag-3 are under research. Along this line, it has been suggested 
that LSECtin, a member of the DC-SIGN family of molecules expressed in the liver and 
also on many tumors, is another ligand for Lag-3 (33). The cytoplasmic tail of Lag-3 
contains a unique KIEELE motif that is essential for the inhibitory function of Lag-3 
(29). 
In mouse model, Lag-3 expression seemed to be strongly correlated with the severity of 
infection (34). As described for Tim-3, also co-expression of Lag-3 with PD-1 is 
characteristic of dysfunctional or exhausted CD8+ T cells (35). Dual blockade of Lag-3 
and PD-1 could potentially reverse exhaustion and anergy among tumour-specific CD8+ 
T cells and virus-specific CD8+ T cells in the setting of chronic infection (2). 
 
TIGIT. T cell immunoglobulin and ITIM domain is a co-inhibitory receptor, member 
of CD28 family, expressed on activated T cells but also found on NK cells, memory T 
cells, a subset of Treg cells as well as follicular T helper (Tfh) cells. The main ligand for 
TIGIT is CD155 (PVR) but it could also bind CD112 (PVRL2, nectin-2), both 
expressed on APCs, T cells and various cell types including tumor cells (29). 
Interestingly, CD226 (DNAM-1) and CD96 (Tactile) interact with the same ligands and 
define a pathway, together with TIGIT, in which CD226 delivers a positive co-
stimulatory signal, in association with the integrin LFA-1 (36). On the contrary, CD96 
and TIGIT deliver inhibitory signals (37) by ITIM motifs in their cytoplasmic tails.  
CD155 and TIGIT are homodimers on the cell surface, and dimerization is essential for 
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their appropriate function (29). As CD155 is highly expressed on cancer cells, the 
binding of TIGIT negatively regulates antitumor responses. As mentioned above 
combined immune checkpoint blockade therapies may restore antitumor immunity in a 
more efficient way. Thus, TIGIT not only synergizes with PD-1 but also with Tim-3 in 
impairing protective antitumor responses (38,39). Interestingly, a recent study 
demonstrated that the blockade of TIGIT prevents NK exhaustion and elicits tumor-




1.4 Phenotypic, functional and molecular features of T-cell exhaustion 
 
As we described before, PD-1 is a crucial regulator of correct immune 
responses. Normally, following the peak of effector expansion, the foreign antigen is 
cleared and PD-1 expression is down regulated. After the clearance of antigen, most 
activated specific T cells die, but a subset persists and transitions into the memory T cell 
pool.	By contrast, during chronic infection and cancer, antigen and inflammation persist 
after the effector phase and PD-1 expression remains high, inducing an altered 
differentiation and functional state, called exhaustion.  
Exhausted T cells were first described in chronic murine lymphocytic choriomeningitis 
virus (LCMV) and then observed also in human infections and cancers. Features of 
exhausted T cells are overexpression of multiple inhibitory receptors, including PD-1, 
Tim-3, Lag-3, 2B4, CD160 and TIGIT, altered metabolism and progressive loss of 
effector function, which typically arise in a hierarchical manner (10). The first steps are 
the reduced IL-2 production, proliferation and cytolytic activity, followed by defects in 
producing various cytokines, such as IFN-γ and tumor necrosis factor (TNF)-α, and 
chemokines as well as in degranulation (10).  
Of note, although PD-1 has been predominantly associated with T exhaustion, it is 
important to remember that it is mainly an effector marker, not a specific exhaustion 
molecule. Thus, high amounts of PD-1 do not necessarily correlate with more exhausted 
phenotype (41). 
 
Different studies demonstrated that the severity of exhaustion strongly depends on the 
level of antigen stimulation and that exhausted T cells did not persist in antigen-free 
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recipients (16,42). Early studies in mouse model revealed that CD8+ T cells infected 
with LCMV only for a week, keep the ability to form fully functional memory T cells 
when the antigen is removed. By contrast, if the antigen presentation persists for 2-4 
week, T cell exhaustion develops and becomes established. At this time, removing 
antigens will not be sufficient to restore T cell functionality and memory differentiation 
(43,44). 
While memory CD8+ T cells can be maintained efficiently long term without antigen 
stimulation via IL-7- and IL-15-driven mediated self-renewal, exhausted T cells show a 
downregulation of CD127 (α-chain of IL-7 receptor) and CD122 (β-chain of IL-2 and 
IL-15 receptors), and are unable to persist in antigen-independent manner.  
Exhausted T cells are not inert, since they are characterized by a hyporesponsive state 
but not complete functional unresponsiveness, thus exhaustion is not irreversible. It has 
been demonstrated that the blockade of PD-1/PD-L1 axis could partly reverse 
exhaustion, restoring effector functions, proliferation, and enhancing viral and tumor 
control (45). Interestingly, recent studies demonstrated that the potential of anti–PD-
1/PD-L1 therapy to restore antiviral and antitumor T cell responses depends on CD28 
expression by T cells (46). Blockade of CD28-binding ligands (CD80, CD86) has also 
been shown to completely reduce the ability of PD-1/PD-L1 blockers to prevent T cell 
exhaustion (46).   
In mouse model, two different subsets of CD8+ exhausted T cells could be defined 
based on the potential rescue by PD-1/PD-L1 checkpoint blockers. In chronic LCMV 
infection, a pool of PD-1low T-bethigh T cells, named progenitor subset, demonstrated 
higher potential of reinvigoration, with higher residual proliferation capacity and 
effector cytokines production, while PD-1high Eomeshigh T cells were defined as 
terminally differentiated, since they did not respond to anti-PD-L1 (47). However, these 
distinct subsets based on Eomes, T-bet and PD-1 expression could not be transferred to 
humans, since heterogeneity within CD8+ exhausted T cells is still unclear. 
Another important transcription factor involved in T cell exhaustion is B lymphocyte-
induced maturation protein-1 (Blimp-1), a negative regulator of B and T terminal 
differentiation. Upregulation of Blimp-1 is associated with high levels of various 
inhibitory receptors as PD-1, Lag-3 and CD160 in exhausted T cells and its deletion 
could restore their expression and induce memory differentiation (48). 
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Nevertheless, various studies are focusing on the way blocking PD-1/PD-L1 pathway 
could affect transcriptional programs, cellular and epigenetic changes of exhausted T 
cells. Pauken et al demonstrated that anti-PD-L1 treatment of exhausted T cells in 
chronic infected mice induced a transcriptional program more similar to effector than 
memory T cells, largely driven by cell-cycle pathway, metabolic alterations and effector 
genes transcription (42). Moreover, exhausted T cells treated with anti-PD-L1 showed 
increased IL-7 signaling. Nevertheless, if antigen persisted even after cessation of 
blockade, exhausted T cells with or without PD-L1 treatment showed similar 
transcriptomic patterns, due to inability of the checkpoint inhibitor to restore memory-
like phenotype or reprogram the epigenetic landscape of exhausted T cells into effector 
or memory T cells. 
 
In conclusion, there are increasing evidence suggesting that exhausted T cells are a 
distinct lineage of CD8+ T cells, since they acquire a distinct epigenetic profile that 
couldn’t be modify by PD-1/PD-L1 blockade. For this reason immune checkpoint 
inhibitors’ efficacy may be restricted, as epigenetic stability of exhausted T cells limits 




1.5 PD-1 expression on NK cells 
 
 Natural killer lymphocytes are cells of the innate immunity that play a 
fundamental role in antiviral and antitumor responses (49).  
Since their discovery in the 1970s, different studies in mice and humans demonstrated 
an anti-tumor activity of NK cells. For example, the infiltration of NK cells into renal 
cell cancer (RCC) is associated with a favorable prognosis (50) and in melanoma has 
been shown to positively correlate with melanocytic lesion regression (51). 
The process of NK cell activation is the result of a fine balance between signals 
mediated by an array of triggering and inhibitory surface receptors (52-54). NK cell 
receptors involved in tumor cell killing include the HLA class I-specific inhibitory 
receptors (i.e. KIRs and CD94/NKG2A) and major activating NK receptors (including 
NKp30, NKp46, NKp44, NKG2D and DNAM-1). In the absence of inhibitory signals 
the interaction between activating receptors and their specific ligands on tumor cells 
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results in NK cell triggering and target cell lysis. The main cellular ligands of activating 
NK receptors include MICA/B, ULBPs (recognized by NKG2D) (55,56), Nectin-2 and 
PVR (recognized by DNAM-1) (36), B7H6 (recognized by NKp30) (57,58) and the 
isoform of the mixed-lineage leukemia-5 protein (MLL5) (recognized by NKp44) (59). 
In most instances, these ligands are not (or only marginally) expressed by normal 
resting cells while they become highly expressed on tumor cells. 
 
It has recently been shown that also NK cells can express PD-1 and can acquire an 
exhausted phenotype. In multiple myeloma (MM) patients, in which disease progression 
is associated with a gradual decline of immune cell function, has been demonstrated a 
role of PD-1/PD-L1 pathway in the NK cell immune response against MM and that an 
anti-PD-1 antibody could enhance NK function against tumor cells (60). 
Another paper reports that PD-1 was upregulated on circulating NK cells of patients 
with Kaposi sarcoma (KS) and associated with strongly altered functional capacities. 
PD-1 was expressed in a sub-population of activated, mature CD56dimCD16pos NK cells 
with otherwise normal expression of NK surface receptors. PD-1pos NK cells from KS 
patients were hyporesponsive ex vivo following direct triggering of NCR or CD16 
activating receptors, or short stimulation with NK cell targets. PD-1pos NK cells failed to 
degranulate and release IFN-γ, but exogenous IL-2 or IL-15 restored this defect (61). 
The expression of PD-1 on mature CD56dimCD16pos NK cells subset had been 
confirmed also in peripheral blood NK cells from ovarian cancer patients. However, the 
proportions of such cells were much higher in the ascitic fluid, suggesting that the 
tumor microenvironment may be responsible for the de novo expression of PD-1 on NK 
cells. Interestingly, all individuals with PD-1+ NK cells in their peripheral blood were 
seropositive for cytomegalovirus (CMV) (62). 
Finally, CD56brightCD16- NK cells have been reported to display high levels of PD-1 in 
patients with lymphoma, suggesting the possibility of inhibition by malignant B cells 
and PDL-1/PD-L2-expressing tumor associated macrophages (63).  
Therapeutic PD-1 blockade may be a strategy for circumventing tumor escape not only 







1.6 PD-1/PD-L1 inhibition in antitumor therapy and potential biomarker 
associated with response 
 
 Since the interaction of PD-1/PD-L1 molecules has a major role in the 
inhibition of effector T cell functions (2), targeting the immuno-regulatory axis PD-
1/PD-L1 represents the most significant approach to restore T cell–mediated antitumor 
immunity. Recently blockade of this pathway has become a corner stone in the current 
management of several different cancers, in particular advanced non-small cell lung 
cancer (NSCLC) and melanoma. Several compounds designed to disrupt this axis are 
currently available in clinical practice as Immune Checkpoint Inhibitors (ICI). Such 
agents include the anti-PD-1 monoclonal antibodies nivolumab and pembrolizumab, as 
well as the anti-PD-L1 monoclonal antibodies atezolizumab, avelumab and durvalumab 
(64-68).  
In spite of the impressive results obtained from these therapies, a large proportion of 
patients still not experience clinical benefit.  
For this reason a great effort has been put to identify the most appropriate candidates for 
PD-1/PD-L1 blockade among patients. However, the identification of robust biomarkers 
able to predict either clinical response or resistance remains elusive. The most deeply 
investigated biomarker is PD-L1, evaluated by immunohistochemistry in tumor tissue. 
Nevertheless, several trials showed some inconsistencies with regards to the value of 
PD-L1 expression as predictor of outcomes (69). Beyond PD-L1, there is an ongoing 
effort to identify biomarkers related to the immune system, which may provide 
additional mechanistic insights into the ways anti-immune checkpoint antibodies exert 
their effects (70-74). 
Tumor-infiltrating lymphocytes (TILs) have been shown to represent a key element 
influencing the behavior of human tumors (75) thus the relative abundance and 
phenotype of specific subsets of TILs have been extensively investigated as potential 
biomarkers for ICIs (76-78). However, this approach is often unfeasible for advanced 
lung cancer patients because of the limited availability of patient material. 
For this reason, a growing interest has developed in circulating immune cells as possible 
biomarkers for outcomes with ICIs in cancer patients.  Current research on this field is 
active to understand whether measurements in blood may inform, or at least 
approximate, about the state of the immune response at the tumor site prior to treatment. 
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On this regard, it has been found that circulating CD8+PD-1+, but not CD8+PD-1- T 
cells, were enriched in T cells specific for patient tumor-antigens and showed direct 
tumor recognition, implying that the circulating CD8+PD-1+ lymphocytes could 
partially mirror tumor-resident antitumor lymphocytes (79). 
Recent studies have further demonstrated that sampling peripheral blood lymphocytes 
may provide insights into the ongoing immune responses induced by ICI. In murine 
model of melanoma it has been demonstrated that PD-L1 blockade could partially 
restore exhausted T cells, inducing a T cell reinvigoration identified as a de novo 
expression of the proliferation marker KI-67, as well as an increased CD8+ T cell to T 
regulatory cells ratio (71). Accordingly, PD-1 blockade in NSCLC patients results in an 
increase of KI-67+PD-1+CD8+ T cells, characterized by an effector-like phenotype 
(CD45RA- CCR7-, CD38+, HLA DR+) (80). 
 
Taking into account the complex interactions between the immune system and cancer, 
little is known about the dynamics of systemic chemokines and cytokines serum levels 
in anti-PD-1/ PD-L1 blockade. Several studies revealed that circulating cytokine values 
correlate with responses to immune checkpoint inhibitors. A recent study in NSCLC 
patients described that decreasing plasma CXCL2 levels and increasing plasma matrix 
metalloproteinase-2 (MMP2) levels, after treatment with PD-1 inhibitor, were 
significantly associated with improved PFS, and that most of the long responders to 
anti-PD-1 therapy maintained these changes in CXCL2 and MMP2 during the course of 
treatment (81). 
Moreover, Sanmamed et al. showed serum IL-8 levels to be highly correlated with 
tumor burden changes in metastatic melanoma and NSCLC patients during treatment 
with anti-PD-1/anti-CTLA-4 therapy. They reported that overall survival (OS) was 
significant longer in PD-1-treated patients presenting early decreases in serum IL-8 
levels than in patients showing early increases (82). Another study on advanced 
melanoma patients treated with nivolumab reported that pretreatment serum IFN-γ, IL-
6, and IL-10 levels were significantly higher in those with tumor progression (83). The 
effects of anti-PD-1, anti-CTLA-4 or combination of these immune checkpoint blockers 
(Combo blockade) demonstrated that each form of treatment was associated with 
distinct pattern of systemic changes in cytokines. In addition, Das R. and colleagues 
described that the levels of IL1α were increased following anti-PD1 and Combo 
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blockade while IFN-γ-induced protein 10 (IP-10, known also as CXCL10) levels were 




1.7 Aims of the study 
 
The goals of our study were : 
 1) to evaluate the signature of the immune system during nivolumab 
therapy in a cohort of patients affected by advanced NSCLC. To this aim, we performed 
a high-dimensional flow cytometry analysis to probe the distribution of lymphocyte 
subsets in the peripheral blood of NSCLC patients before and during anti-PD-1 
immunotherapy, and to verify whether peculiar immune cell signatures could effectively 
be related to the clinical outcomes.  
 2) to profile changes in plasma levels of a range of chemokines, 
cytokines, and growth factors in order to correlate them with clinical outcome to 
nivolumab therapy. To this aim, we performed the analysis of a panel of various soluble 


















2. PATIENTS AND METHODS 
 
2.1 Study population and assessment of clinical outcomes 
 
 The study was designed as part of a mono-institutional translational 
research within our Institution. The study included patients receiving nivolumab for 
advanced NSCLC within the global Italian nivolumab Expanded Access Program 
(EAP), which was designed to allow patients affected by advanced NSCLC to receive 
nivolumab in the timespan between its registration and its availability in Italy as 
therapeutic standard (NCT02475382).  The main eligibility criteria for the treatment 
with nivolumab included cytological or histological diagnosis of advanced NSCLC, 
progression after at least one line of platinum-based chemotherapy for advanced 
disease, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≤ 2; the 
main exclusion criteria included the necessity to assume systemic corticosteroid 
treatment at a dose > 10 mg/die of prednisone (or equivalent) and the presence of 
uncontrolled brain metastases. Notably, the determination of PD-L1 expression was not 
required for the inclusion within EAP. Eligible patients received nivolumab at 3 mg/Kg 
every 14 days until death or unacceptable toxicity, or up to 96 weeks from the first 
administration; in case of progressive disease (PD), treatment continuation was allowed 
if clinical benefit was perceived. Those patients who were candidate to receive 
nivolumab within the Italian EAP at our Institution were asked to participate to an 
additional translational research designed to explore potential predictive biomarkers of 
outcomes with nivolumab; the study was approved by our local Ethical Committee.  
 
 
   2.2. Response assessment 
 
 The enrolled patients underwent disease assessment after every 4 
administrations of nivolumab. Response assessment was performed by using the 
Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1; additionally, since 
RECIST could underestimate the activity of ICI, an additional response assessment was 
performed by using the immune-related response criteria (irRC) (85). In case of PD 
according to either RECIST or irRC, the subsequent CT scan was performed after 2 
cycles instead of 4 for confirmation of progression. The best overall response (BOR) 
	 18	
achieved during the whole treatment with nivolumab was recorded for both RECIST 
and irRC according to the following categories: complete response (CR), partial 
response (PR), stable disease (SD), progressive disease (PD); those patients who died 
before undergoing at least one radiologic response assessment were categorized as early 
death (ED). Based on these categories, for our analyses, patients were then clustered in: 
i) controlled disease (CD) group, which comprised every patient displaying CR, PR, 
SD, or ii) progressive disease group (PD). Notably, ED patients were not considered 
within the PD group, apart from one longitudinal analysis reported in Figure 8.  
Overall survival (OS) time was recorded from the first administration of nivolumab to 
the date of death or date at last clinical examination. PFS time was recorded from the 
first administration to the date of progression according to RECIST (RECIST-PFS) or 
irRC (irRC-PFS) or date at last clinical examination. If a patient died before 
experiencing disease progression, PFS was set equal to OS time. 
 
 
2.3. Blood collection and isolation of peripheral blood mononuclear cells  
 
 Blood samples were collected before each administration of nivolumab. 
Thus, we analyzed blood samples at baseline (T0) and at the subsequent collection 
timings (every 15 days) defined as T1, T2, T3, up to 4 therapy cycles (Fig.3). The 
rationale for limiting the number of samples to 4 for each patient was to evaluate the 
early landscape of circulating immune cells from baseline to the time of the first 
radiologic assessment (planned after the fourth administration of nivolumab).  
 
 



















Blood samples were collected using EDTA as anti-coagulant. Upon collection, plasma 
was separated by a first centrifugation step at 1800 rpm at 4 °C for 10 min. The 
supernatant was carefully collected and centrifuged a second time at 1800 rpm at 4 °C 
for 10 min; finally, the supernatants were made to aliquots and stored in -20°C until 
assayed.  
After plasma separation, blood samples were quickly processed by Ficoll-Hypaque 
(Cedarlane) density gradient centrifugation to isolate peripheral blood mononuclear 
cells (PBMCs). PBMCs were then counted, aliquoted and stored in liquid nitrogen for 
subsequent flow cytometry analyses.  
 
 
2.4 Flow cytometry 
 
 To comprehensively investigate the phenotype of blood lymphocyte 
populations, PBMCs were thawed and incubated in complete medium (RPMI 1640 
supplemented with 10% FCS, Penicillin /Streptomycin) overnight at 37°C (79). Then 
samples were washed, resuspended in 50 µl PBS and then stained with four different 
multicolor staining panels. Monoclonal antibodies used for the staining are reported in 
detail in Table 1. For the detection of surface markers, cells were incubated with a 
combination of antibodies for 20-30 min, at 4°C. For intranuclear antigens detection, 
cells were washed twice with PBS after surface staining and then additionally fixed and 
permeabilized using the Fix/Perm solution (eBioscience) for 30 min at room 
temperature. After washing, cells were resuspended in 1× Permeabilization Buffer 
(eBioscience) containing a mixture of antibodies for 40 min at room temperature. 
 Samples were then acquired using Gallios (Beckman Coulter) flow cytometer, and data 
analyzed with FlowJo 10.3 software (TreeStar Inc.). Appropriate forward/side scatter 
and live cell selection with LIVE/DEAD FixableAqua Dead dye (Invitrogen, L34957, 
dil: 1:500) or 7Amino-Actinomycin D (BD, 559925,dil 1:20) was performed to identify 
different peripheral lymphocyte sub-populations. Staining panels and representative 








Antigen Fluorocrome Clone Source Dilution Code 
7AAD 
 
  BD 1:20 559925 
FixableAqua 
Dead dye  
 
  Invitrogen 1:500 L34957 
CD127 PE/ DAZZLE A019D5  Biolegend 1:100 351336 
CD25 BV421 M-A251 BD 1:25 562442 
CD3 APC-R700 UCHT1 BD 1:100 565119 
CD3 VioBlue BW264/56 MILTENYI 1:100 
130-094-
363 
CD39 BB515 TU66 BD 1:25 565469 
CD4 PC7 SFCI12T4D11 Coulter 1:200 737660 
CD45 APC-H7 2D1 BD 1:100 560178 





(HLDA6) Coulter 1:100 A21692 
CD69 PE-CF594 FN50 BD 1:50 562617 
CD8  APC RPA-T8 BD 1:100 
561952/ 
561953 
EOMES FITC WD1928 eBioscience 1:50 11-4877-42 
FOX P3 
AlexaFluor 
647 259D/C7 BD 1:50 
560889/ 
560045 
Granzyme B PE- CF594 GB11 BD 1:200 562462 
KI-67 Per-CP-Cy 5.5 B56 BD 1:100 561284 
KLRG 1 PE-Cy 7 2F1/KLRG1  Biolegend 1:75 138415/6 
PD-1 PE J105 eBioscience 1:75 12-2799-42 
TIM-3 BV421 7D3 BD 1:200 565563 






A     
     B 
 
Figure 4. (A) Representative flow cytometry plots showing gating strategy for correlate 
analysis of peripheral lymphocyte subpopulations. (B) Histograms show frequency of PD-1+ 
cells among CD3+ T cells, CD8+ T cells, CD4+ T cells, NK cells, CD3+CD56+ T cells, for one 
representative patient. Gating strategy was performed using Fluorescence Minus One (FMO) for 
each marker as control. 
 
 
2.5 Plasma samples  
 
We evaluate levels of various soluble factors including lymphokines, interferons, 
colony stimulating factors and chemokines through different MILLIPLEX® MAP Kits, 
(MAGPIX® System (Luminex® xMAP® Technology, Merck Millipore, Germany) as 
reported in Table 2. These panels give the opportunity to perform a simultaneous 
quantification of a large number of cytokines, so that we could achieve a global 
overview of soluble factors’ distribution in our samples. 
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Plasma samples were thawed at 4°C overnight and then centrifuged at 2000g for 10 
minutes to removed lipids. Each patient sample was run using 25 µl of plasma.   
 
Milliplex Map Kit Cytokines/chemokines 
HCYTOMAG-60K EGF, FGF-2, G-CSF, Fractalkine, IFNα2, IL-12 p40, IL-12 
p70, IL-15, IL-1ra, IL-1α, IL-1β, IL-7, IL-8, IP-10, MCP-1, 
TNFβ, VEGF 
HCYP3MAG-63K CXCL11, CCL19 
HCD8MAG-15K CD137, Fas, FasL, GM-CSF, Granzyme A e B, IFNγ, IL-2, 
IL-4, IL-5, IL-6, IL-10, IL-13, MIP-1a, MIP-1b, Perforina,  
TNFa,  
HTH17MAG-14K IL-17a, IL-25, IL-21, IL-22, IL-23, IL-27, IL-33, MIP-3a,  
HCYP2MAG-62K CXCL13, CXCL12 




Protein levels were expressed as OD value as measured by Microplate Reader AD200 
Beckman, according to manufacturer’s instruction for each plate. 
 
 
2.6 Statistical analysis  
 
 Distributions of all immune biomarker measurements and patients’ 
characteristics (gender, age at enrollment, time since diagnosis, ECOG-PS, number of 
previous treatments, histotype, disease stage and smoking habit) were explored and 
summarized using descriptive statistics. In particular, continuous variables (e.g., 
biomarkers and age at enrollment) were described through mean, median and range of 
variation (min-max). Data relative to biomarkers were also dichotomized using median 
values as cut-off points in order to obtain equally sized subgroups. All categorical and 
discrete variables (e.g., gender and ECOG-PS) were expressed in terms of absolute and 
relative frequencies (percentages). Differences in immune biomarker distribution in 
sub-groups of patients were assessed using the nonparametric Kruskal-Wallis test. 
Kaplan-Meier method was applied to describe the effect of each dichotomized immune 
biomarker on PFS/OS probabilities while the association between all immune 
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biomarker and relapse/death rates was estimated by means of the Cox regression 
analysis and expressed as rate (hazard) ratio (HR) which represents the rate of 
relapse/death in the higher immune biomarker category relative to the analogous rate in 
the lower category. 
To evaluate the association between each baseline dichotomized immune biomarker 
measurement and RECIST/irRC binary BOR outcome (PD vs CD), a logistic regression 
analysis was performed. In this setting, odds ratio (OR), namely the ratio of progressive 
patients’ proportion in the higher immune biomarker category to the analogous 
proportion in the lower category, was calculated as an index of association. 
Finally, in order to assess the impact of the RECIST/irRC BOR variable (PD vs CD) on 
the time trajectory of all individual immune biomarker measurements from T0 (cycle 1) 
to T3 (cycle 4), a random effects regression analysis was applied to log-transformed 
immune biomarker data. In this context, median ratio (MR), that is the ratio of median 
immune biomarker value among PD patients and the median immune biomarker value 
among CD patients, was used as an index of association. 
In all regression settings, baseline patients’ characteristics were taken into consideration 
as confounding factors and statistical inference on HR/OR/MR was carried out using 
the likelihood ratio test. Ninety-five percent confidence limits (95% CL) were also 
computed for all indexes. 
A two-tailed p-value < 0.050 was assumed as statistically significant.  
All analyses were performed using Stata (StataCorp. Stata Statistical Software. Release 
13.1. College Station, TX (USA), 2013). 
Data from plasma samples analysis had been performed using GraphPad Prism v7.0e 
(GraphPad Software Inc.). Correlation of values obtained from MILLIPLEX® MAP 













3.1 Study population and patients outcomes 
 
 Globally, 74 patients were enrolled within our Institution. The baseline 
clinical and pathological characteristics are reported in Table 3 and were used as 
covariates in the subsequent correlation analyses. Notably, only two patients had EGFR 
mutation, one harboring exon 19 deletion and one harboring exon 19 deletion and exon 
20 insertion, while no ALK or ROS1 rearrangement was reported. The median number 
of nivolumab administrations was 6 (range: 1-46).  
Three patients were not evaluable for BOR assessment as the best response CT scan 
was not available, while one patient was not evaluable for PFS assessment, as he/she 
did not undergo further CT scans. Notably, one patient was considered evaluable for 
irRC BOR and PFS but not for RECIST BOR and PFS, due to differences between the 
criteria. All the patients were evaluable for OS analysis. 
 
 
Table 3. Summary of patients’ characteristics. Abbreviations: ECOG-PS, Eastern Cooperative 
Oncology Group Performance Status 
 
Patients’ characteristics N % Mean SD Min-Max 
Gender      Male 51 68.9    Female 23 31.1    Age   67.6 9.0 44.0-85.0 
≤ 70 years 37 50.0    > 70 years 37 50.0     
Time since diagnosis   2.4 2.1 0.0-11.3 
≤ 2 years 37 50.0    >2 years 37 50.0    ECOG-PS      0 27 36.5    
≥ 1 47 63.5    
Previous treatments      1 30 40.5    >1 43 58.1    Histotype      
Squamous cell lung cancer 15 20.3    Adenocarcinoma 
 59 79.7    










   
   
PD-L1      0% 40 54.1    
≥ 1% 7 9.5    Missing 27 36.5    
Whole sample 74 100.0     
	1	
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The median OS, RECIST-PFS and irRC-PFS time were 8.60, 1.87 and 1.93 months, 
respectively.  
The RECIST-BOR was reported as follows: PR = 10; SD = 14; PD = 30; the irRC-BOR 
was reported as follows: PR = 9; SD = 19; PD = 27. No complete responses were 
observed. Overall, 16 patients died before undergoing the first response assessment, and 
were defined as ED. Notably, smoking habit, PD-L1 status and disease stage were 
excluded from analyses since they resulted to be irrelevant, affected by missing data 
(36%) and with strongly imbalanced categories (lower stage = 3 pts. vs higher stage = 
74 pts), respectively. 
Blood specimens for PBMC isolation and immunophenotyping were available for 73 




3.2 Peripheral blood lymphocyte sub-populations  
 
 To gain insights in the mechanisms underlying the clinical responses to 
anti-PD-1 therapy in cancer patients, we comprehensively evaluated the frequency and 
phenotype of immune cell populations potentially involved in the response to human 
tumors (namely T cells and NK cells) in PBMCs of patients receiving nivolumab. By 
the use of multicolor flow cytometry (Fig. 4A-B), we assessed the frequency of total 
circulating T cells and NK cells, as well as the relative abundance of CD8+ and CD4+ T 
cell subsets. Among CD8+ T cells, we also quantified the frequency of bona fide 
exhausted T cells by gating on PD-1+ EOMES+ CD8+ T cells, as previously described 
(71). In addition, because of a key role in the modulation of immune responses, we 
investigated the impact of regulatory CD4+ CD25+ CD127- Foxp3+ T cells (defined as 
Tregs), including those co-expressing CD39 (CD39+Tregs) (86) in our samples. Given 
the cytotoxic potential of CD3+CD56+ T cells, we also identified and monitored this 







3.3 Baseline PB immune features and survival 
 
 First, the impact of the baseline immunological status (pre-therapy) on 
OS, RECIST-PFS and irRC-PFS upon nivolumab treatment was evaluated. Figure 5 
(caterpillar plot) summarizes the effect of each biomarker on patient’s life expectancy 
through HR (Hazard Ratio) point estimates and corresponding 95%CL, obtained from 
the Cox regression analysis. HR is the ratio of the death/relapse rate in higher immune 
biomarker levels to the analogous rate in lower levels. When HR > 1, higher immune 
biomarker levels (i.e., greater than median value) are correlated with higher 
death/relapse rates.  
Our results suggest that higher levels of almost all the effector T cell subsets, namely 
CD3+, CD8+ and CD4+ T cells were correlated with longer OS and PFS, (HR < 1 for 
both indicators). Along this line, also higher percentage of circulating exhausted CD8+ 
T cells was associated, albeit not reaching statistical significance, with longer OS (HR = 
0.66; 95%CL = 0.37-1.18) and PFS (HR = 0.85; 95%CL = 0.50-1.44) (by IRRC only). 
As far as activated T cells are concerned, the role of CD3+CD56+ T cells was not clear. 
Within our cohort, patients displaying percentage of CD3+CD56+ T cells higher than the 
median were associated with longer OS (HR = 0.72; 95%CL = 0.41-1.27), but with 
shorter PFS (HR = 1.09; 95%CL = 0.65-1.82; HR = 1.11, 95%CL = 0.66-1.86, by 
RECIST and IRRC respectively). Similarly, with regards to total Treg cells and CD39+ 
Treg cells, we did not find any significant correlation between their amounts and OS or 
PFS, but only a trend towards higher baseline frequency of CD39+ Tregs in patients 
characterized by longer OS (HR = 0.84, 95%CL = 0.47-1.51) and PFS (0.84 RECIST; 
0.88 IRRC). 
Given that high value of CD8+ T cells to Treg ratio have been linked with higher rate of 
response to immune checkpoint inhibitors (71), we also assessed whether patients with 
high (CD8+/CD39+ Treg) ratio showed better OS and/or clinical benefit. Surprisingly, 
we did not find any improvement in terms of survival for patients with higher baseline 
CD8/CD39+ Treg ratio in our cohort upon treatment; rather, higher values were 
associated with lower OS (HR = 1.96, 95%CL = 1.04-3.72) and RECIST-PFS (HR = 
1.53, 95%CL = 0.85-2.75). This may be due to a trend towards a higher baseline 
frequency of CD39+ Tregs in patients characterized by longer overall survival.  
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 Next, in order to define whether the survival advantage that results from 
possessing higher frequency of effector T cells could be actually related to a higher 
proportion of PD-1+ cells within each subset, we also analyzed the expression of this 
immune biomarker on the various sub-populations previously defined (Fig. 4B). Despite 
some studies have reported that therapeutic anti–PD-1 administration hampers detection 
of PD-1 expression on peripheral blood cells by commercially available antibodies, we 
did not notice any technical issue on this regard. In contrast with what was expected 
(10,87), higher expression levels of PD-1 on CD3+ cells and on CD8+ T cells were 
significantly associated with poor OS and PFS, and a similar trend was observed on 
CD3+CD56+ T cells (HR = 1.39, 95%CL = 0.79-2.45, HR = 1.42, 95%CL = 0.84-2.37, 
HR = 1.57, 95%CL = 0.94-2.6 for OS, PFS RECIST and PFS IRRC respectevely). On 
the contrary, no correlation between PD-1 levels on CD4+ T cells and survival was 
detected (OS: HR = 0.75, 95%CL = 0.41-1.34; PFS: HR = 0.92, 95%CL = 0.52-1.60; 
HR = 0.96, 95%CL = 0.55-1.67, by RECIST and IRRC respectively) (Fig. 5). Overall, 
these data suggest that higher baseline levels of PD-1 expression on effector T cells may 
limit clinical efficacy of nivolumab treatment. 
 
Concerning the innate immune response, high frequencies of NK cells were correlated 
with lower OS (HR = 2.72, 95% CL = 1.46-5.08) and PFS (HR = 1.88, 95% CL = 1.08-
3.26; HR = 2.22, 95% CL = 1.25-3.96, by RECIST and IRRC respectively). Moreover, 
we found that a discrete subset of NK cells actually expressed PD-1 on their surface 
(0,6-10%). Nonetheless, the role of PD-1 expressed by NK cells was unclear, since we 
did not find a significant correlation with OS (HR = 0.85, 95% CL = 0.48-1.52), 
whereas only a slight association with PFS (HR = 0.8, 95% CL = 0.46-1.36; HR = 0.74, 
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Figure 5. Caterpillar plots showing the impact of each immune biomarker evaluated at 
baseline on overall survival (OS), RECIST and irRC progression-free survival (PFS). Hazard 
ratio (HR, represented by a plus sign) and corresponding 95% confidence limits (95%CL, 
represented by horizontal “whiskers”) were derived from a Cox regression analysis adjusted for 
gender, age at enrollment, time since diagnosis, ECOG-PS, number of previous treatments and 
histotype. Vertical line at HR = 1 divides HR associated with a better prognosis (left side) from 
those associated with a worsen prognosis (right side). 
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Our data were further confirmed using multivariate analyses (Cox curves) (Fig.6). 
Patients were categorized in high and low groups based on the median cut-off value of 
the each marker. Although statistical significance was not observed for several of the 
analyzed markers, relative amounts of circulating CD3+ cells and NK cells could predict 
patients’ overall survival time (p = 0.048 and p = 0.002, respectively). These data 
reinforce the notion that the relative abundance of CD3+ T cells and NK cells could 
represent, respectively, positive and negative prognostic markers of survival in our 
cohort. Moreover, the CD8/CD39+Treg ratio emerged as a biomarker able to predict the 
clinical outcome, since higher values (> 23.2) at baseline were associated with shorter 
OS (p = 0.037)(Fig. 6A). 
We also noticed that baseline PD-1 expression was generally correlated with poor 
clinical outcomes. In particular, high expression of PD-1 on CD3+ cells (> 29.3% ) and 
on CD8+ T cells (>32.8%) were both significantly associated with shorter OS (p = 0.013 
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Figure 6. (A) Kaplan-Meier survival curves illustrating the prognostic effect on OS of CD3+T 
cells, CD56+CD3- NK cells and CD8+/CD39+Treg ratio for patients with higher (dotted lines) 
and lower  (solid lines) cell counts. (B) Kaplan–Meier survival curves for patients with high or 
low expression of PD-1 on CD3+ T cells and on CD8+ T cells. The median values used as 
thresholds for categorizing immune biomarkers are indicated in the left plots of each curve. 
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3.4 Baseline PB immune features and radiological response  
 
 Next, we wondered whether, beside OS, immunological signatures 
measured at baseline could also be prognostic of clinical response (i.e. RECIST and 
irRC) to nivolumab treatment. Notably, analyses using irRC criteria didn’t show any 
relevant difference from RECIST. As show in Figure 7, in agreement with our data 
correlating immune biomarkers and survival, higher frequency of total CD3+ 
lymphocytes (HR= 0.92, 95% CI= 0.26-3.21) and total CD4+ T cells (HR=0.28, 95% 
CI= 0.07-1.06) were also associated with controlled disease. Along the same line, 
higher amounts of both total Tregs and CD39+ Tregs cells were significantly correlated 
with clinical benefit (T regs: HR=0.38, 95% CI= 0.09-1.55; CD39+Tregs: HR=0.33, 
95% CI=0.08-1.32). Conversely, higher frequency of NK cells was associated with a 
progressive disease, in line with results correlated to survival (HR=1.77, 95% CI=0.52-
5.99). 
   
Moreover, consistent with previous observation regarding the negative impact of PD-1 
expression on patients’ OS, we found that PD patients significantly differed from CD 
patients by displaying higher level of PD-1 on almost all lymphocyte sub-populations 
examined (CD3+, CD4+, CD8+, CD3+CD56+) (Fig.7). Thus, again suggesting that PD-1 
expression on circulating T lymphocytes, at baseline, might negatively impact on 
patient’s clinical response and survival. In Figure 7 we reported results from analysis of 
each biomarker; OR is to be interpreted as the ratio of the proportion of progressive 
patients in higher immune biomarker levels to the analogous proportion in lower levels.  
 
Surprisingly, in contrast to what was found by analyzing OS, we found that higher 
frequency of CD8+ T cells and of CD3+CD56+ T cells significantly correlated with 















Figure 7. Caterpillar plot showing the effect of each immune biomarker evaluated at baseline 
on PD vs CD in relation with best overall response (BOR), defined according to RECIST 
criteria. Odds ratio (OR, represented by a plus sign) and corresponding 95% confidence limits 
(95%CL, represented by horizontal “whiskers”) were derived from a logistic regression analysis 
adjusted for gender, age at enrollment, time since diagnosis, ECOG-PS, number of previous 
treatments and histotype. OR is to be interpreted as the ratio of the proportion of progressive 
patients in higher immune biomarker levels to the analogous proportion in lower levels. Vertical 
line at OR = 1 divides OR associated with a responsive disease (left side) from those associated 





Of note, by repeating the same multivariate Cox regression analysis including also 
early-death (ED) patients within the PD group (Fig. 8), we confirmed that there was a 
trend toward clinical benefit in patients who had higher frequencies of CD3+ T cells, 
CD4+ T cells, total and CD39+ Tregs, while higher amount of CD8+ T cells, NK cells 
and overall PD-1 expression were associated with a poor outcome.  In particular, high 
frequency of CD4+ T cells was correlated with controlled disease, while PD-1 
expression on CD3+ T cells and on CD3+ CD56+ T cells, as well as a high CD8+/CD39+ 
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Figure 8. Caterpillar plot showing the effect of each immune biomarker, evaluated at baseline 
on PD+ED patients vs CD patients. Odds ratio (OR, represented by a plus sign) and 
corresponding 95% confidence limits (95%CL, represented by horizontal “whiskers”) were 
derived from a logistic regression analysis adjusted for gender, age at enrollment, time since 
diagnosis, ECOG-PS, number of previous treatments and histotype. Vertical line at OR = 1 
divides OR associated with a responsive disease (left side) from those associated with a 
progressive disease (right side). Statistically significant P-values derived from the likelihood 
ratio test are reported in the graph. 
 
We further investigated each of the above-mentioned parameters with univariate 
analysis and similar results were obtained. Remarkably, while not reaching statistical 
significance on multivariate model, univariate analysis showed that the impact of 
exhausted T cells on the response rate was remarkable. Of note, although exhausted T 
cells were supposed to be the target sub-population of ICI, the baseline frequency was 
significantly higher in PD patients than in CD patients (Fig. 9 p= 0.046).  
This data suggests that the amount of exhausted T cells may be considered a potential 




Figure 9. Distribution of CD8+PD-1+Eomes+ 
T   cells according to binary (CD vs PD) best 
overall response (BOR). Statistical comparison 
between the two distributions was performed 
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3.5 Changes in PB lymphocytes during anti-PD-1 therapy 
 
 Finally, we aimed at identifying whether variations in immunological 
biomarkers, assessed during the treatment, could be associated with disease control. To 
this end, we performed a longitudinal analysis of blood samples obtained at baseline 
and before each treatment cycle, up to six weeks. Remarkably, those patients who died 
before the first response assessment, categorized as early death (ED), were excluded 
from longitudinal analyses as they could not undergo all the four pre-planned blood 
sample collections. We found that in PD patients the frequencies of CD8+ T cells, 
exhausted T cells, and CD3+CD56+ T cells were significantly higher than median values 
of the CD group. Figure 10 shows the relationship between CD vs PD best overall 
response (BOR) on the longitudinal profile of all immune biomarkers. MR represents 
the ratio of each immune marker median value in PD to CD groups. These data, again, 
highlighted the putative role of exhausted T cells as a prognostic biomarker.  
 
     
Figure 10. Caterpillar plot showing the relationship between the binary (CD vs PD) best 
overall response (BOR) on the longitudinal profile of all immune biomarkers. Median ratio 
(MR, represented by a plus sign) and corresponding 95% confidence limits were derived from a 
random effects regression analysis adjusted for gender, age at enrollment, time since diagnosis, 
ECOG-PS, number of previous treatments and histotype. Vertical line at MR = 1 divides MR 
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Thus, when longitudinally analyzed in each group of patients, we found that the 
frequency of exhausted T cells among total lymphocytes was lower in CD than PD 
patients. Interestingly, in CD patients level of exhausted T cells immediately decreased 
from baseline after the first cycle of therapy (p-value = < 0,0001), then reaching plateau 
as long as at day 45 of treatment (Fig. 11).  Conversely, it is worth noting that levels of 
exhausted T cells in PD patients did not show significant variations across the different 
time points.  Moreover exhausted T cell levels were consistently higher in PD than in 
CD patients during treatment. 
Similarly, the difference of CD8+ T cells and of CD3+CD56+ T cells frequencies 
between CD and PD patients persisted during therapy (p-value = 0.016 and 0.045 


















Figure 11. Frequency of CD8+ exhausted T cells at four different time points (Pre-treatment, 
post 15 days, post 30 days and post 45 days) in PD and in CD patients. Significative correlation 
of exhausted population between CD and PD groups is reported in the upper parte of the figure, 
for each time point. Statistical significance was calculated using Mann-Whitney test. At the 
bottom are reported differences inside each group during therapy. Statistical significance was 


















































































3.6 CD69 expressing NK cells are higher in Controlled Disease patients 
 
 Our previous results showed that higher frequency of NK cells at 
baseline was correlated with poor response. We further analyzed the expression of 
CD69 activation marker on peripheral blood NK cells derived from NSCLC patients 
treated with nivolumab. 
We found that, at baseline, CD patients showed a significant higher percentage of 
CD69+ NK cells. Moreover, after the first therapy cycle, CD69+ NK cell levels were 
consistently higher in CD than in PD patients (Fig. 12). 
These results suggest that CD69+ NK cells could represent potential biomarker 




Figure 12. Frequency of CD69+ NK cells at two different time points (Pre-treatment, post 15 
days) in CD and in PD patients. Statistical significance was calculated using Two-way ANOVA 




























3.7  Soluble factors in plasma samples during anti-PD-1 therapy 
 
 As checkpoint blockade led to modifications in circulating immune cells, 
we hypothesized that these therapies could also lead to detectable changes in systemic 
levels of cytokines. Accordingly, we evaluated changes in the plasma levels of a panel 
of 46 cytokines/chemokines/growth factors in 10 CD and 10 PD patients at baseline 
(Pre-treatment), post 15 days and post 45 days of treatment, using Luminex analysis. 
Of the analytes tested, our results showed that IFN-γ-induced protein 10 (IP-10) and 
monocyte chemoattractant protein 1 (MCP-1 also known as CCL2) significantly 
increased during treatment in CD patients (Fig. 13). Similarly, albeit not reaching 
statistical significance, we found higher plasma levels of both vascular endothelial 
growth factor (VEGF) and epithelial growth factors (EGF) in CD patients during 
therapy (data not shown).   
These data suggest that the modulation of IP-10 and MCP-1 soluble factors in NSCLC 
patients during nivolumab therapy may represent novel circulating biomarker of 





Figure 13. Changes in plasma cytokines and chemokines evaluated in CD and PD NSCLC 
patients, treated with nivolumab, at different time points: Pre-treatment (T0), after 15 days (T1) 
and 45 days (T3) from the beginning of therapy. Statistical analysis was performed using Two-







































































 In recent years, therapies that block immune checkpoints, thereby 
enhancing antitumor immune responses, have revolutionized the treatment of many 
solid malignancies, including melanoma and NSCLC. Although these tumors are 
reported to be high immuno-genic, the immune system often fails to eliminate cancer 
cells. It is now clear that tumors co-opt certain immune-checkpoint pathways as a major 
mechanism of immune resistance.  
Among the most important and promising immunological approaches to re-activate 
antitumor immunity has emerged the blockade of PD-1/PD-L1 axis with monoclonal 
antibodies. 
Patients and tumors may respond unpredictably to immunotherapy partly owing to 
heterogeneity of the immune composition and phenotypic profiles of TILs within 
individual tumors and between patients. Thus, a significant number of patients treated 
fails to have a clinical benefit from immunotherapies and the molecular mechanism 
underling this negative response is still unknown. Identification of predictive 
biomarkers is a priority in the field of cancer immunotherapy, in order to monitor or 
predict patients’ response to appropriate treatment. 
 
While immunotherapy with PD-1/PD-L1 blocking agents has achieved impressive 
results in the management of advanced NSCLC, reliable biomarkers of efficacy are still 
required. This study was designed to determine whether the proportions of circulating T 
cells sub-populations could represent potential predictors of outcomes for NSCLC 
patients receiving nivolumab. 
With regards to baseline values, our data revealed that patients owning higher frequency 
of CD3+ T cells and of distinct T cell subsets (i.e CD4+, CD8+, and CD3+CD56+ T cells) 
showed a survival advantage upon nivolumab treatment. Conversely, relative high 
proportions of NK cells, as well as a higher CD8+/CD39+ Treg ratio, were associated 
with shorter OS and PFS; along this line, also possessing high levels of PD-1 appeared 
to play a role in limiting patients’ survival.  
These data are in line with what observed by Mazzaschi and coworkers reporting that in 
NSCLC a low expression of PD-1 among CD8+ TILs was associated with prolonged 
progression-free survival (PFS) during treatment with nivolumab (78).  
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Consistently to what found by analyzing OS, our data showed that baseline higher 
frequencies of total CD3+ T cells, CD4+ T cells, total Tregs and CD39+ Tregs were 
correlated with controlled disease, whereas higher proportions of NK cells, as well as a 
high CD8+/CD39+Treg ratio, were found in PD patients. A remarkable exception 
regards the amount of CD8+ T cells that, in contrast to what found by analyzing patients 
survival, was significantly correlated with progressive disease.  
These data suggest that while some sub-populations associated with survival were also 
associated with radiological response in a consistent fashion (ie: CD3+ and CD4+ 
effector T cells were associated with improved response and survival, while NK cells 
were associated with worse response and survival), other sub-populations appeared to 
behave differently, in terms of response and survival. This apparent inconsistency might 
be explained by the peculiar mechanism of action of immune checkpoint inhibitors, 
which might achieve prolonged survival while their effect in terms of response might be 
underestimated by radiological response evaluation criteria (this is especially true with 
regards to RECIST).  
Interestingly, in line with data regarding the inverse correlation between overall PD-1 
expression and OS, we found that at baseline higher PD-1 levels on T cells were strictly 
associated with poor outcome. This data suggests that baseline PD-1 amount on 
lymphocytes may represent a predictive biomarker correlated with both survival and 
response.  
Remarkably, univariate analysis showed that the frequency of exhausted T cells at 
baseline was higher in PD patients, thus highlighting the possible role of this CD8+ T 
cell sub-population as a predictive factor associated with response.  
It should be stressed that our present analysis was done on PB lymphocytes and thus our 
results might not completely mirrored what found analyzing CD8+ T cells present at the 
tumor site. Indeed, data collected from metastatic melanoma samples suggest that a 
higher proportion of exhausted CD8+ among TILs predicts response to PD-1/PD-L1 
blockade, implying that the relative composition of TIL populations might impact on 
the outcomes achieved by immune checkpoint inhibitors (77). 
 
Our present data suggest that levels of PB exhausted T cells during nivolumab therapy 
may be associated with clinical outcome, though this association needs to be confirmed 
by larger studies. 
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Along this line, longitudinal peripheral blood samples from patients revealed that, both 
at baseline and before each treatment cycle, the frequency of exhausted T cells was 
higher in PD as compared to CD patients. Moreover, in CD group the amount of 
exhausted T cells declined soon after the first therapy cycle and then remained stable 
until the fourth administration, whereas in PD patients exhausted T cells levels 
alternatively increased and decreased at different time points.  
These results support the notion that levels of circulating exhausted T cells might be 
used to identify patients who will experience clinical disease control with nivolumab. 
However, additional studies with detailed analysis of exhausted T population levels in 
peripheral blood during late weeks after PD-1 blockade are needed.  
Thus, if these results will be confirmed and extended also at later time points, peripheral 
blood analysis of exhausted T cell subsets may provide a valuable strategy to predict 
responses to PD-1–targeted therapy that may assist in the management of lung cancer 
patients. 
 
Although T cells are believed to play the primary role in the anti-tumor immunity of 
checkpoint blockade therapies, the potential role of non-T cell population cannot be 
excluded. In this study we found that CD patients showed higher frequency of CD69+ 
NK cells than PD patients both at baseline and after the first cycle of nivolumab 
therapy. As CD69 is an activation marker, it’s reasonable to think that CD69+ NK cells 
might represent a more functional subset, playing a role in antitumor immune response. 
Thus, we could assume that higher frequency of CD69+ NK cells potentially correlates 
with clinical benefit to anti-PD-1 treatment.  
Notably, it had been reported that also NK cells could express PD-1 and that in vitro 
blockade of PD-1 pathway reverted the NK cell functional defects induced by PD-
1/PDL-1 interactions (62). Therefore, immune checkpoint inhibitors might act also on 
NK cells, helping to circumvent tumor escape and boost T cell-mediated antitumor 
immune activity by enhancing NK-cell trafficking and effector functions against the 
tumor.  
 
In this study, we also assessed variations in plasma levels of several chemokines and 
cytokines in NSCLC patients treated with nivolumab. Although the majority of 
analyzed soluble factors didn’t show any relevant variation, possible due to the fact that 
they probably act locally in the tumor microenvironment, we found an increase of 
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plasma IP-10 and MCP-1 levels from baseline to T1 (post 15 days) and T3 (post 45 
days) time points in CD patients. Under proinflammatory conditions, IP-10 is secreted 
in response to IFN-γ from a variety of cells, such as leukocytes, activated neutrophils, 
eosinophils, monocytes, epithelial cells, endothelial cells, stromal cells (fibroblasts) and 
keratinocytes. This crucial regulator of the interferon response preferentially attracts 
activated Th1 lymphocytes to the area of inflammation. IP-10 is also a chemo-attractant 
for monocytes, T cells and NK cells (88). 
In our study, higher plasma levels of IP-10, found in CD patients could be in agreement 
with a model in which nivolumab induces IP-10 production by myeloid cells at 
inflammatory sites in tissue in order to recruit immuno-competent T cells to the tumor 
microenvironment (89).  
 
MCP-1 is produced by many cell types, including endothelial, fibroblasts, epithelial 
cells. However, monocyte/macrophages are found to be the major source of MCP-1, 
which regulates the migration and infiltration of monocytes, memory T lymphocytes, 
and NK cells (90). MCP-1 has been shown to exert both pro- and anti-tumor effects. 
Elevated MCP-1 expression levels in the tumor microenvironment as well as high 
circulating concentrations of this chemokine have been associated with poor prognosis 
in breast carcinoma patients. Moreover, MCP-1 has also been shown to mediate the 
recruitment of specific monocyte populations that support the establishment of 
metastatic disease. Conversely, MCP-1 may also recruit antitumor immune cells to 
tumor bed and is required for efficient immunosurveillance, implying that the inhibition 
of MCP-1 may support metastatic spread (91).  
MCP-1 is known to be released during immune responses causing stimulation of both 
macrophages and T cells (92,93). Thus, in the current study, the upregulation of MCP-1 
found in patients with clinical benefit could represent an “anti-PD-1-induced” immune 
response. 
Taken together, since IP-10 and MCP-1 can be easily measured by minimally invasive 
blood sampling, they could be potential prognostic biomarkers for monitoring of 
clinical outcomes in NSCLC patients receiving PD-1 inhibitor therapy. 
 
 We are aware that the possible conclusions of our study might be limited 
by the relatively small number of evaluated patients, especially when the longitudinal 
assessment is taken into account, as some patients did not undergo all the pre-planned 
	 42	
sample collections due to early treatment discontinuation; in spite of this, our research 
might provide an insight on the dynamic immunologic mechanisms leading to different 
efficacy of PD-1 blocking agents and suggests a potential predictive role of both 
circulating immune cell sub-populations and plasma factors during treatment with 
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